Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
|Articles|December 8, 2011

MRI Not Quite There for Lymph Node Diagnosis in Breast Cancer

Author(s)Todd Neff

Magnetic resonance imaging’s accuracy in detecting cancer in the lymph nodes of newly diagnosed breast cancer patients is nothing to sniff at – 80 percent with diffusion-weighted MRI and 85 percent with axial T1-weighted MRI, Canadian researchers have reported. But it’s not quite high enough to skip a lymph node dissection, according to a study published online Dec. 5 in the journal Radiology.

Magnetic resonance imaging’s accuracy in detecting cancer in the lymph nodes of newly diagnosed breast cancer patients is nothing to sniff at – 80 percent with diffusion-weighted MRI and 85 percent with axial T1-weighted MRI, Canadian researchers have reported. But it’s not quite high enough to skip a lymph node dissection, according to a study published online Dec. 5 in the journal Radiology.

University of Toronto researchers chose 61 women (average age 53) with invasive breast cancer to undergo preoperative breast MRI. Axial T1-weighted MRI without fat saturation and diffusion-weighted (DW) MR images were analyzed by two experienced radiologists uninformed of the pathology findings.

They found the sensitivity, specificity, and accuracy to be 88 percent, 82 percent, and 85 percent, respectively, for axial T1-weighted MR imaging and 84 percent, 77 percent, and 80 percent for diffusion-weighted (DW) imaging. Apparent diffusion coefficients (ADCs) were significantly lower in the malignant group.

The team concluded that unenhanced MRI techniques showed high accuracy in the preoperative evaluation of patients with invasive breast cancer, and that, while the results indicated reliable and reproducible assessment with DW imaging, “it is unlikely to be useful in clinical practice.”

Related to this article

Emerging Research Insights and New Advances in Neuroradiology
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Current Perspectives on Integrating AI into Radiology
In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.